Inactive Instrument

Neos Therapeutics, Inc. Stock

NEOS

US64052L1061

Latest news : Neos Therapeutics, Inc.

23/06/25	Aytu Biopharma, Inc. Announces Amendment No. 6 to Loan and Security Agreement with Eclipse Lender	CI
01/02/22	Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers	CI
22/03/21	Aytu BioScience : Completes Merger With Neos Therapeutics	MT
22/03/21	Neos Therapeutics, Inc. Announces Board Changes	CI
22/03/21	Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer	CI
22/03/21	Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer	CI
22/03/21	Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index	CI
19/03/21	Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index	CI
19/03/21	Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..	CI
19/03/21	Neos Therapeutics, Inc. - Shareholder/Analyst Call
13/03/21	Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis	MT
11/02/21	Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March	MT
08/02/21	Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.	CI

More news

Press Releases: Neos Therapeutics, Inc.

22/03/21	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)	AQ
22/03/21	Neos Therapeutics : Aytu BioScience Announces Close of Merger with Neos Therapeutics	PU
13/03/21	Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	GL
11/03/21	Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	GL
11/02/21	Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021	GL

More press releases

Managers and Directors: Neos Therapeutics, Inc.

Manager	Title	Age	Since
Gerald McLaughlin CEO	Chief Executive Officer	58	27/06/2018
Mark Oki DFI	Director of Finance/CFO	57	-
Margaret Cabano COO	Chief Operating Officer	-	01/01/2005

Director	Title	Age	Since
Gerald McLaughlin BRD	Director/Board Member	58	27/06/2018

More insiders

Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.

Employees

213

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
NEOS Stock

The best tools reserved for subscribers to boost the performance of your investments!

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/3/21	James Robinson	Issuer sale	Director	82,860	0.1665%
19/3/21	Bryant Fong	Issuer sale	Director	140,215	0.2818%
19/3/21	Beth Hecht	Issuer sale	Director	138,715	0.2788%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOS THERAPEUTICS, INC.	-2.54%	+24.18%	-	-	49.26M
ELI LILLY AND COMPANY	+1.93%	+3.85%	+51.05%	+166.24%	1,089B
JOHNSON & JOHNSON	+0.29%	+6.43%	+60.47%	+52.87%	643B
ABBVIE INC.	+2.45%	+2.77%	+39.61%	+74.48%	465B
ROCHE HOLDING AG	-0.45%	+10.14%	+41.08%	+35.29%	359B
NOVARTIS AG	-0.28%	+3.81%	+37.37%	+42.88%	303B
ASTRAZENECA PLC	+1.29%	+3.20%	+17.48%	+17.18%	267B
NOVO NORDISK A/S	+0.11%	+5.23%	-3.08%	-38.44%	226B
AMGEN INC.	+4.48%	+7.33%	+30.47%	+66.31%	212B
GILEAD SCIENCES, INC.	+2.91%	+3.10%	+18.84%	+74.76%	167B
Average	+0.49%	+5.07%	+32.59%	+54.62%	414.57B
Weighted average by Cap.	+0.64%	+5.14%	+40.88%	+79.79%

Neos Therapeutics, Inc. Stock

Stocks

NEOS

US64052L1061

Pharmaceuticals

Latest news : Neos Therapeutics, Inc.

Press Releases: Neos Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Neos Therapeutics, Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile